Mounjaro Cost in India 2026: Price, Dosage & Results

Mounjaro is the brand name for tirzepatide, a once-weekly injection made by Eli Lilly. Unlike older GLP-1 drugs, it activates two gut-hormone receptors — GIP and GLP-1. This dual action reduces appetite, slows how fast the stomach empties, and improves how the body handles blood sugar, so you eat less without constant hunger or “food noise.”

It was launched in India in March 2025 and quickly became the country's top-selling drug by monthly sales. In India it is a Schedule H prescription medicine — it cannot be sold without a valid prescription.

Mounjaro is priced by dose strength, not a flat monthly fee. As of 2026, reported list prices run from about ₹13,125/month at 2.5 mg up to roughly ₹25,781/month at 15 mg. Most people start low and titrate up over several months, so early months cost less. Prices vary by city, pharmacy and format (KwikPen vs vial). See the table below.

In the SURMOUNT-1 trial, adults with obesity lost an average of up to ~20–22.5% of body weight over 72 weeks on the 15 mg dose, alongside diet and activity changes — results previously only seen with bariatric surgery. Outcomes depend on dose, consistency, protein intake and muscle-preserving exercise, and cannot be guaranteed.

The most common side effects are gastrointestinal and usually fade within the first few weeks: nausea, vomiting, diarrhoea, constipation and reduced appetite. Starting at a low dose and titrating slowly reduces them. Rare but serious risks include pancreatitis, gallbladder problems and a boxed warning for thyroid C-cell tumours. A qualified doctor should screen your history before prescribing.

With MetaFit you complete a short online health review, then a qualified clinician evaluates whether tirzepatide is appropriate for your biology — checking BMI, blood markers, family and medication history. If suitable, medication is prescribed and delivered to your door, paired with AI coaching, protein-focused nutrition and strength training so you lose fat, not muscle.